NYSE American - Delayed Quote USD

Oragenics, Inc. (OGEN)

1.1300

0.0000

(0.00%)

At close: April 19 at 3:59 PM EDT

1.1300

0.00

(0.00%)

After hours: April 19 at 7:48 PM EDT

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

SARASOTA, Fla., April 19, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April 18, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards. Specifically, the letter states that the Company is not in compliance with the conti

Business Wire 5 hours ago
Oragenics, Inc. Files 10K and Provides Company Update

SARASOTA, Fla., April 01, 2024--Oragenics, Inc. (the "Company") (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has filed its annual report on March 29, 2024. The Company is pleased to report it has executed on its strategy to diversify its product development portfolio and makes progress in transforming the Company to create long term value. Some key items that have helped to improve t

Business Wire 18 days ago
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

SARASOTA, Fla., March 18, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. James "Jim" Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II clinical trial. Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion. ONP-002 i

Business Wire last month
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

SARASOTA, Fla., March 05, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it is preparing to undertake the final steps of GMP manufacturing and formulation of its drug candidate for its expected Phase IIA clinical trial. The drug candidate is expected to be combined with its novel intranasal device, for the treatment of mild Traumatic Brain Injury, aka concussion. Oragenic

Business Wire last month
Oragenics Announces Closing of Public Offering

SARASOTA, Fla., March 01, 2024--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced the closing of its previously announced underwritten public offering of 1,400,000 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $2.1 million, before deducting underwriting discounts, and offering expenses pa

Business Wire last month
Oragenics Announces Pricing of Public Offering

SARASOTA, Fla., February 28, 2024--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced the pricing of an underwritten public offering of 1,400,000 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $2.1 million, before deducting underwriting discounts and offering expenses payable by the Company

Business Wire last month
Oragenics Announces Proposed Public Offering

SARASOTA, Fla., February 27, 2024--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants to purchase shares of common stock ("Pre-Funded Warrants") in lieu thereof) in an underwritten public offering. The Company expects to grant the underwriters a 45-day

Business Wire last month
Oragenics, Inc. Announces Leadership Transition

SARASOTA, Fla., February 12, 2024--Oragenics, Inc. (NYSE American: OGEN) (the "Company"), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that, on February 12, 2024, the Company and Kimberly Murphy, the Company’s Chief Executive Officer, entered into a mutually agreeable Separation Agreement (the "Separation Agreement"), pursuant to which Ms. Murphy’s employment with the Company terminated effective Febr

Business Wire 2 months ago
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

SARASOTA, Fla., February 07, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that its engagement agreement with its investment bank has expired and that it does not intend to extend the engagement at this time due to market conditions.

Business Wire 2 months ago
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

SARASOTA, Fla., February 05, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced it is preparing for a Phase II clinical trial using its novel drug - device combination for the treatment of mild Traumatic Brain Injury, aka concussion. Oragenics’ lead drug candidate, ONP-002, is a new chemical entity (NCE) designed to target the brain through self-propelled powdere

Business Wire 2 months ago
Oragenics Announces Termination of At-The-Market Offering Program

TAMPA, Fla., January 23, 2024--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") today announced it has terminated its previously announced "at-the-market" ("ATM") equity offering program.

Business Wire 2 months ago
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets

TAMPA, Fla., January 02, 2024--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") announces it has completed its previously announced acquisition of assets related to Odyssey Health, Inc.’s (OTCQB: ODYY) ("Odyssey") proprietary neurological drug therapies and technologies.

Business Wire 3 months ago
Oragenics Issues Update to Shareholders

TAMPA, Fla., November 02, 2023--Oragenics, Inc. (NYSE American: OGEN):

Business Wire 5 months ago
Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

TAMPA, Fla., October 18, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") announced the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors effective October 4, 2023.

Business Wire 5 months ago
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate

TAMPA, Fla. & LAS VEGAS, October 05, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") and Odyssey Health, Inc. (OTCQB: ODYY) ("Odyssey") announce the signing of a definitive agreement under which Oragenics will acquire Odyssey’s assets related to its proprietary neurological drug therapies and technologies. The assets include drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as

Business Wire 6 months ago
Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

TAMPA, Fla., September 29, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") and Lantern Bioworks announce a groundbreaking partnership, marked by the formalization of a materials transfer agreement. This milestone follows rigorous testing and validation of Oragenics’ biological samples, which are poised to potentially revolutionize dental caries prevention by replacing harmful bacterial strains with non-pathogenic counterparts.

Business Wire 6 months ago
Oragenics, Inc. Announces Private Placement

TAMPA, Fla., August 07, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), biotech company dedicated to fighting infectious diseases including coronaviruses, today announced it has entered into definitive agreements with two healthcare-focused investors, in which the Company issued in a private placement (the "Private Placement Offering"), an aggregate of (i) 404,728 shares of the Company’s common stock, $0.001 par value (the "Common Stock"), and (ii) 404,728 shares of S

Business Wire 8 months ago
Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

TAMPA, Fla., June 05, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotechnology company dedicated to fighting infectious diseases, announces the award of a grant from CQDM, a Canadian bioresearch consortium, for the collaborative development of a variant-agnostic COVID-19 protein subunit vaccine candidate. The project, which aims to build upon Oragenics’ current lead intranasal vaccine candidate NT-CoV2-1, is a collaboration with the National Research Council of

Business Wire 10 months ago

Performance Overview

Return	OGEN	S&P 500
YTD	-79.93%	+4.14%
1-Year	-65.23%	+19.55%
3-Year	-97.35%	+18.68%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Oragenics, Inc. (OGEN)

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Oragenics, Inc. Files 10K and Provides Company Update

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Closing of Public Offering

Oragenics Announces Pricing of Public Offering

Oragenics Announces Proposed Public Offering

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Termination of At-The-Market Offering Program

Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets

Oragenics Issues Update to Shareholders

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

Oragenics, Inc. Announces Private Placement

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

Performance Overview